Emilie Kuster, DNP, ARNP | |
433 E 8th St, Port Angeles, WA 98362-6219 | |
(360) 565-0999 | |
Not Available |
Full Name | Emilie Kuster |
---|---|
Gender | Female |
Speciality | Nurse Practitioner |
Experience | 5 Years |
Location | 433 E 8th St, Port Angeles, Washington |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1366001406 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
363L00000X | Nurse Practitioner | AP60971565 (Washington) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Bonner General Hospital | Sandpoint, ID | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Sandpoint Family Health Center, Pllc. | 3779598404 | 6 |
News Archive
Ventas, Inc. today announced that Moody's Investors Service has raised the rating on the Company's senior unsecured debt to Baa3 from Ba1, with a stable outlook. This action by Moody's follows similar ratings upgrades from Fitch Ratings in July 2009 (unsecured debt raised to BBB from BBB-, with a stable outlook) and Standard & Poor's Ratings Services in February 2008 (unsecured debt raised to BBB- from BB+, with a stable outlook). The Company's senior unsecured debt now carries an investment grade rating from all three major ratings agencies.
Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel oncology compounds that target cancer stem cells (CSCs), today announced that it holds the license, from the University of Pittsburgh ("Pitt"), for the exclusive worldwide rights to a clinically active oncology vaccine directed to multiple defined targets on tumor bulk and CSCs.
Every day in intensive care units across the country, patients get aggressive, expensive treatment their caregivers know is not going to save their lives or make them better. California researchers now report this so-called "futile" care has a hidden price: It's crowding out other patients who could otherwise survive, recover and get back to living their lives.
When it comes to benefiting from experimental treatments offered in cancer clinical trials, your health insurance status and where you live matters, according to results of two new research studies to be presented at the 2019 ASCO Quality Care Symposium, held September 6 and 7 in San Diego.
The results of an interventional trial presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) showed that use of the disease-modifying anti-rheumatic drug hydroxychloroquine for 24 weeks did not diminish mild-moderate pain from primary hand osteoarthritis (OA).
› Verified 1 days ago
Entity Name | Sandpoint Family Health Center, Pllc. |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1881613321 PECOS PAC ID: 3779598404 Enrollment ID: O20060216000034 |
News Archive
Ventas, Inc. today announced that Moody's Investors Service has raised the rating on the Company's senior unsecured debt to Baa3 from Ba1, with a stable outlook. This action by Moody's follows similar ratings upgrades from Fitch Ratings in July 2009 (unsecured debt raised to BBB from BBB-, with a stable outlook) and Standard & Poor's Ratings Services in February 2008 (unsecured debt raised to BBB- from BB+, with a stable outlook). The Company's senior unsecured debt now carries an investment grade rating from all three major ratings agencies.
Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel oncology compounds that target cancer stem cells (CSCs), today announced that it holds the license, from the University of Pittsburgh ("Pitt"), for the exclusive worldwide rights to a clinically active oncology vaccine directed to multiple defined targets on tumor bulk and CSCs.
Every day in intensive care units across the country, patients get aggressive, expensive treatment their caregivers know is not going to save their lives or make them better. California researchers now report this so-called "futile" care has a hidden price: It's crowding out other patients who could otherwise survive, recover and get back to living their lives.
When it comes to benefiting from experimental treatments offered in cancer clinical trials, your health insurance status and where you live matters, according to results of two new research studies to be presented at the 2019 ASCO Quality Care Symposium, held September 6 and 7 in San Diego.
The results of an interventional trial presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) showed that use of the disease-modifying anti-rheumatic drug hydroxychloroquine for 24 weeks did not diminish mild-moderate pain from primary hand osteoarthritis (OA).
› Verified 1 days ago
Mailing Address | Practice Location Address |
---|---|
Emilie Kuster, DNP, ARNP 433 E 8th St, Port Angeles, WA 98362-6219 Ph: (360) 565-0999 | Emilie Kuster, DNP, ARNP 433 E 8th St, Port Angeles, WA 98362-6219 Ph: (360) 565-0999 |
News Archive
Ventas, Inc. today announced that Moody's Investors Service has raised the rating on the Company's senior unsecured debt to Baa3 from Ba1, with a stable outlook. This action by Moody's follows similar ratings upgrades from Fitch Ratings in July 2009 (unsecured debt raised to BBB from BBB-, with a stable outlook) and Standard & Poor's Ratings Services in February 2008 (unsecured debt raised to BBB- from BB+, with a stable outlook). The Company's senior unsecured debt now carries an investment grade rating from all three major ratings agencies.
Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel oncology compounds that target cancer stem cells (CSCs), today announced that it holds the license, from the University of Pittsburgh ("Pitt"), for the exclusive worldwide rights to a clinically active oncology vaccine directed to multiple defined targets on tumor bulk and CSCs.
Every day in intensive care units across the country, patients get aggressive, expensive treatment their caregivers know is not going to save their lives or make them better. California researchers now report this so-called "futile" care has a hidden price: It's crowding out other patients who could otherwise survive, recover and get back to living their lives.
When it comes to benefiting from experimental treatments offered in cancer clinical trials, your health insurance status and where you live matters, according to results of two new research studies to be presented at the 2019 ASCO Quality Care Symposium, held September 6 and 7 in San Diego.
The results of an interventional trial presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) showed that use of the disease-modifying anti-rheumatic drug hydroxychloroquine for 24 weeks did not diminish mild-moderate pain from primary hand osteoarthritis (OA).
› Verified 1 days ago
Lauren Kate Ballou, ARNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 240 W Front St, Ste A, Port Angeles, WA 98362 Phone: 360-452-7891 Fax: 360-452-8087 | |
Kalli M Jones, CPNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 2844 W Edgewood Dr, Port Angeles, WA 98363 Phone: 360-460-9493 | |
Sophia Felder, MSN, FNP-C, IBCLC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 907 Georgiana St, Port Angeles, WA 98362 Phone: 360-565-0999 | |
Susan Bach, Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 118 E 8th St, Port Angeles, WA 98362 Phone: 360-457-0431 Fax: 360-457-0493 | |
Caren Ellington, NP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 907 Georgiana St, Port Angeles, WA 98362 Phone: 360-565-0550 Fax: 360-565-0551 | |
Margaret M Depew, ARNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 118 E 8th St, Port Angeles, WA 98362 Phone: 360-457-0431 Fax: 360-457-0493 | |
Michelle L Turner, ARNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 303 W 8th St, Port Angeles, WA 98362 Phone: 360-457-8578 Fax: 360-457-4841 |